(Adds details, background, shares)
Aug 7 (Reuters) – Zynerba Pharmaceuticals Inc said
on Monday its synthetic cannabis-based gel to treat epilepsy
failed a mid-stage study, sending the U.S. drug developer’s
shares plunging 50 percent.
In the study, two doses of Zynerba’s gel — also its lead
experimental drug — were tested in adults suffering from
epilepsy with partial seizures, those that occur when epileptic
activity takes part in a localized part of the brain.
Neither dose induced a statistically significant improvement
in seizure frequency, when compared to a placebo.
Data from studies evaluating the gel’s use in osteoarthritis
patients and in children with Fragile X Syndrome, a genetic
condition, is expected later this year.
Zynerba’s gel contains a synthetically processed formulation
of cannabidiol (CBD), a non-psychoactive component of the
Although many U.S. states have sanctioned the medical or
recreational use of cannabis, drugs derived from the plant could
take longer than usual to hit